HERCEPTIN CONCURRENT WITH EXTERNAL BEAM RADIATION -BREAST CANCER

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究为II期研究。在一项II期研究中，医生们正试图了解他们正在研究的疗法是否对治疗癌症有效果。本研究的目的是确定赫赛汀和外部束辐射的组合对治疗乳腺癌的有效性。赫赛汀是一种针对Her-2-neu抗原（蛋白质）的人造单克隆抗体，已发现癌症过度产生Her-2-neu抗原。已发现赫赛汀有助于控制过度产生Her-2-neu蛋白的患者的转移性乳腺癌。在本研究中，赫赛汀将用作放射增敏剂。放射增敏剂是一种增加癌细胞对辐射的反应性的药物。在这项研究中，研究人员试图了解通过给予赫赛汀，肿瘤细胞是否会对辐射产生更大的反应。赫赛汀和外照射的结合是实验性的，不是这种乳腺癌的标准治疗方法

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is a phase II study. In a phase II study, doctors are trying to learn whether the therapy they are investigating has an effect on treating cancer. The purpose of this research study is to determine how effective the combination of Herceptin and external beam radiation are on treating breast cancer. Herceptin is a man-made monoclonal antibody directed to the Her-2-neu antigen (protein) which cancer has been found to over-produce. Herceptin has been found to help control metastatic breast cancer in patients that over-produce the Her-2-neu protein. In this study, Herceptin will be used as a radiosensitizer. A radiosensitizer is a drug that increases the responsiveness of the cancer cells to radiation. In this study researchers are trying to see if by giving Herceptin, tumor cells will become more responsive to the radiation. The combination of Herceptin and external beam radiation is experimental, not the standard treatment for this type of breast cancer